Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage.

van Dijk A, Naaijkens BA, Jurgens WJ, Oerlemans R, Scheffer GL, Kassies J, Aznou J, Brouwer M, van Rossum AC, Schuurhuis GJ, van Milligen FJ, Niessen HW.

Cell Biol Toxicol. 2012 Oct;28(5):303-15. doi: 10.1007/s10565-012-9225-y. Epub 2012 Jul 17.

PMID:
22801743
2.

(-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.

Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M.

Phytomedicine. 2010 Apr;17(5):356-62. doi: 10.1016/j.phymed.2010.01.001. Epub 2010 Feb 10.

PMID:
20149610
3.

A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.

Graber-Maier A, Gutmann H, Drewe J.

Mol Pharm. 2010 Oct 4;7(5):1618-28. doi: 10.1021/mp100040f. Epub 2010 Aug 11.

PMID:
20701289
4.

Effect of oxygen on multidrug resistance in the first trimester human placenta.

Lye P, Bloise E, Dunk C, Javam M, Gibb W, Lye SJ, Matthews SG.

Placenta. 2013 Sep;34(9):817-23. doi: 10.1016/j.placenta.2013.05.010. Epub 2013 Jun 20.

PMID:
23790363
5.
6.

ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.

Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU.

Hematology. 2009 Aug;14(4):204-12. doi: 10.1179/102453309X426218.

PMID:
19635183
7.

Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.

Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, Sugimoto Y.

Cancer Chemother Pharmacol. 2007 Nov;60(6):789-97. Epub 2007 Mar 8.

PMID:
17345086
8.

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib.

Dufour R, Daumar P, Mounetou E, Aubel C, Kwiatkowski F, Abrial C, Vatoux C, Penault-Llorca F, Bamdad M.

Sci Rep. 2015 Aug 3;5:12670. doi: 10.1038/srep12670.

10.

The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.

Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, Azzariti A, Pagliarulo A.

Mol Cancer. 2013 May 24;12:47. doi: 10.1186/1476-4598-12-47.

11.

Preliminary study of the effects of ╬▓-elemene on MCF-7/ADM breast cancer stem cells.

Dong Y, Li L, Wang L, Zhou T, Liu JW, Gao YJ.

Genet Mol Res. 2015 Mar 27;14(1):2347-55. doi: 10.4238/2015.March.27.20.

12.

Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).

Doyle L, Ross DD.

Oncogene. 2003 Oct 20;22(47):7340-58. Review.

PMID:
14576842
13.

Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.

Sun Z, Zhao Z, Li G, Dong S, Huang Z, Ye L, Liang H, Qu J, Ai X, Zhang W, Chen X.

Tumori. 2010 Jan-Feb;96(1):90-6.

14.

Effect of oxygen on multidrug resistance in term human placenta.

Javam M, Audette MC, Iqbal M, Bloise E, Gibb W, Matthews SG.

Placenta. 2014 May;35(5):324-30. doi: 10.1016/j.placenta.2014.02.010. Epub 2014 Mar 18.

PMID:
24685282
15.

Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.

Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F.

Clin Exp Pharmacol Physiol. 2006 Jan-Feb;33(1-2):58-65.

PMID:
16445700
16.

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.

Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, Nakayama H, Kawaguchi T, Saito H.

Pharm Res. 2008 Apr;25(4):827-35. Epub 2007 Oct 13.

PMID:
17934801
17.

Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.

Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheper RJ, Scheffer GL, de Witte TJ, Raymakers RA.

Clin Cancer Res. 2005 Mar 15;11(6):2436-44.

19.

Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.

Herzog M, Storch CH, Gut P, Kotlyar D, F├╝llekrug J, Ehehalt R, Haefeli WE, Weiss J.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Jan;383(1):1-11. doi: 10.1007/s00210-010-0568-8. Epub 2010 Oct 10.

PMID:
20936466
20.

ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.

Daood M, Tsai C, Ahdab-Barmada M, Watchko JF.

Neuropediatrics. 2008 Aug;39(4):211-8. doi: 10.1055/s-0028-1103272. Epub 2009 Jan 22.

Supplemental Content

Support Center